Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal GSK256066 in Seasonal Allergic Rhinitis
2006-006710-15Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in seasonal allergic rhinitis (SAR) comparing Intranasal GSK256066 sequences with Intranasal placebo periods (2 arms). Primary endpoints: Effects of GSK256066 on RNA biomarkers of PDE4 inhibition and Effects of GSK256066 on protein biomarkers of PDE4 inhibition. Started Mar 2007; status: completed.
02
Drugs
GSK256066
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2006-006710-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006710-15.